Company Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need.
It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate.
It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jun 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Dr. Martin H. Huber M.D. |
Contact Details
Address: 840 Memorial Drive Cambridge, Massachusetts United States | |
| Website | https://www.mersana.com |
Stock Details
| Ticker Symbol | MRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001442836 |
| CUSIP Number | 59045L106 |
| ISIN Number | US59045L1061 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin H. Huber M.D. | President, Chief Executive Officer & Director |
| Alejandra Veronica Carvajal J.D. | Senior Vice President, Secretary & Chief Legal Officer |
| Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer & Chief Operating Officer |
| Ashish Mandelia | Chief Accounting Officer |
| Chuck Miller | Senior Vice President of Regulatory Affairs |
| Dr. Timothy B. Lowinger Ph.D. | Senior Vice President and Chief Science & Technology Officer |
| Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications |
| Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. |
| Mikhail Papisov Ph.D. | Co-Founder |
| Mohan Bala Ph.D. | Senior Vice President & Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 4 | Filing |
| Oct 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 07, 2024 | 4 | Filing |
| Oct 07, 2024 | 4 | Filing |
| Oct 07, 2024 | 4 | Filing |